Peer-reviewedCC BY-NC-NDCancer science
Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition.
40 affiliations
- 1Department of Medical Genetics and Genomics, Saitama Cancer Center, Saitama, Japan.
- 2Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- 3Aichi Cancer Center Research Institute, Aichi, Japan.
- 4Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- 5Department of Genome Medical Science and Medical Genetics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
- 6Department of Clinical Genetics Unit, Shimane University Faculty of Medicine, Shimane, Japan.
- 7Department of Clinical Genetic Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.
- 8Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- 9Department of Genomic Medicine, Fujita Health University, Aichi, Japan.
- 10Department of Clinical Genetics, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- 11Division of Clinical Genetics/Support Centre for Genetic Medicine, Kanazawa University Hospital, Kanazawa, Japan.
- 12Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
- 13Department of Specialized Surgeries, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- 14Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
- 15Department of Genomic Medicine, Mie University Hospital, Tsu, Mie, Japan.
- 16Department of Life Sciences and Bioethics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
- 17Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- 18Department of Clinical Genomics, The University of Tokyo Hospital, Tokyo, Japan.
- 19Department of Early Clinical Development, Kyoto University Hospital, Kyoto, Japan.
- 20Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, Hokkaido, Japan.
- 21Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
- 22Department of Hereditary Tumors, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
- 23Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
- 24Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- 25Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
- 26Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- 27Department of Neuro-Oncology, International Medical Center, Saitama Medical University, Saitama, Japan.
- 28Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- 29Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- 30Department of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan.
- 31Department of Clinical Genetics, NHO Nagoya Medical Center, Aichi, Japan.
- 32Division of Genetic Medicine Promotion, Shizuoka Cancer Center, Shizuoka, Japan.
- 33Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
- 34Department of Breast and Thyroid Surgery, Kochi Health Science Center, Kochi, Japan.
- 35Clinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan.
- 36Cancer Genetics Laboratory, Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
- 37Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
- 38Laboratory of Laboratory/Sports Medicine, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
- 39Department of Genetic Oncology, Hereditary Tumors, Osaka International Cancer Institute, Osaka, Japan.
- 40Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Abstract
In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the "Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition." Unlike conventional phenotype-based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer-affected and cancer-free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene-specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence-based management strategies for 56 cancer-susceptibility genes, this guidance facilitates the shift toward genotype-driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision-making for patients and their relatives.
Related
- Organization of the first national workshop for families in Switzerland concerned with hereditary cancer syndromes.
- Single-Gene Overexpression of Pigeon Pea (Cajanus cajan) CcSBPase or CcSHMT1 and Multigene Overexpression of CcSBPase with CcSTN7 Do Not Impact Physiological Responses to Water Deficit Stress in Tobacco (Nicotiana tabacum)
- PrimeStack editors enable efficient and site-specific integration of large multigene cargos in plants
- Results Of PMP22 Gene Deletion and Duplication Analysis in 100 Patients with Hereditary Neuropathy
- Face Processing Impairments in Dementia Syndromes: A Systematic Review
BibTeX
@article{yoshida2026japanese,
title = {{Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition.}},
author = {Reiko Yoshida and Akira Hirasawa and Issei Imoto and Tatsuro Yamaguchi and Kensuke Kumamoto and Momoko Araki and Arisa Ueki and Kenta Masuda and Yusaku Urakawa and Noriko Tanabe and Atsushi Watanabe and Makoto Hirata and Tomoyuki Aruga and Takeshi Kuwata and Yoshinaga Okugawa and Keika Kaneko and Hiroko Terui-Kohbata and Megumi Matsumoto and Sayaka Ueno and Katsutoshi Oda and Hisako Ono and Akihiro Sakurai and Hirotaka Matsui and Gou Yamamoto and Hideki Yamamoto and Yasuko Yamamoto and Masachika Ikegami and Yusuke Ohkuma and Kazuhiko Shien and Shigenobu Suzuki and Shunsaku Takayanagi and Masahiko Tanabe and Hisashi Hasumi and Naohito Hatta and Hiroyoshi Hattori and Hiroyuki Matsubayashi and Wataru Yamagami and Masayoshi Yamada and Kazuyuki Oishi and Tomomi Oka and Shinya Oda and Yusuke Kobayashi and Kazuhiro Takekoshi and Takeshi Nakajima and Yoshiko Nakano and Yoshiko Nakayama and Fumiharu Miura and Yasuyuki Miyakura and Yoshiko Mori and Akiyo Yoshimura and Masato Yonamine and Kunitoshi Shigeyasu and Hiroko Fujita and Mashu Futagawa and Kouji Ohta and Junko Kawano and Tomoharu Tokutomi and Ayaka Sato and Takeshi Makabe and Tomoko Yoshihama},
journal = {Cancer science},
year = {2026},
month = oct,
doi = {10.1111/cas.70566},
url = {https://europepmc.org/article/MED/42925246},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes With Multigene Panel Testing, 2025 Edition.
AU - Reiko Yoshida
AU - Akira Hirasawa
AU - Issei Imoto
AU - Tatsuro Yamaguchi
AU - Kensuke Kumamoto
AU - Momoko Araki
AU - Arisa Ueki
AU - Kenta Masuda
AU - Yusaku Urakawa
AU - Noriko Tanabe
AU - Atsushi Watanabe
AU - Makoto Hirata
AU - Tomoyuki Aruga
AU - Takeshi Kuwata
AU - Yoshinaga Okugawa
AU - Keika Kaneko
AU - Hiroko Terui-Kohbata
AU - Megumi Matsumoto
AU - Sayaka Ueno
AU - Katsutoshi Oda
AU - Hisako Ono
AU - Akihiro Sakurai
AU - Hirotaka Matsui
AU - Gou Yamamoto
AU - Hideki Yamamoto
AU - Yasuko Yamamoto
AU - Masachika Ikegami
AU - Yusuke Ohkuma
AU - Kazuhiko Shien
AU - Shigenobu Suzuki
AU - Shunsaku Takayanagi
AU - Masahiko Tanabe
AU - Hisashi Hasumi
AU - Naohito Hatta
AU - Hiroyoshi Hattori
AU - Hiroyuki Matsubayashi
AU - Wataru Yamagami
AU - Masayoshi Yamada
AU - Kazuyuki Oishi
AU - Tomomi Oka
AU - Shinya Oda
AU - Yusuke Kobayashi
AU - Kazuhiro Takekoshi
AU - Takeshi Nakajima
AU - Yoshiko Nakano
AU - Yoshiko Nakayama
AU - Fumiharu Miura
AU - Yasuyuki Miyakura
AU - Yoshiko Mori
AU - Akiyo Yoshimura
AU - Masato Yonamine
AU - Kunitoshi Shigeyasu
AU - Hiroko Fujita
AU - Mashu Futagawa
AU - Kouji Ohta
AU - Junko Kawano
AU - Tomoharu Tokutomi
AU - Ayaka Sato
AU - Takeshi Makabe
AU - Tomoko Yoshihama
PY - 2026
DA - 2026/10/24
JO - Cancer science
DO - 10.1111/cas.70566
UR - https://europepmc.org/article/MED/42925246
AB - In March 2025, the Japanese Society for Hereditary Tumors and the Ministry of Health, Labour and Welfare (MHLW) Research on Promotion of Cancer Control Program Grant Number JPMH 23EA1037 published the "Japanese Society for Hereditary Tumors Guidance: Hereditary Cancer Syndromes with Multigene Panel Testing (MGPT), 2025 Edition." Unlike conventional phenotype-based guidelines, this guidance promotes preemptive cancer medicine based on genotype. The guidance establishes standardized criteria for MGPT eligibility, emphasizing its utility in both cancer-affected and cancer-free individuals to identify actionable germline pathogenic variants (GPVs). Key recommendations include the integration of gene-specific curation for variant interpretation and the implementation of structured clinical practice systems for risk management. By providing evidence-based management strategies for 56 cancer-susceptibility genes, this guidance facilitates the shift toward genotype-driven oncology. This digest assists healthcare providers in utilizing MGPT and supports shared decision-making for patients and their relatives.
SN - 1347-9032
SN - 1349-7006
ER -